Key Developments: Boston Scientific Corp (BSX)

BSX on New York Consolidated

13.15USD
19 Dec 2014
Price Change (% chg)

$-0.11 (-0.83%)
Prev Close
$13.26
Open
$13.28
Day's High
$13.38
Day's Low
$13.15
Volume
18,616,603
Avg. Vol
12,760,201
52-wk High
$14.08
52-wk Low
$11.10

Search Stocks

Latest Key Developments (Source: Significant Developments)

Boston Scientific Corp narrows FY 2014 revenue outlook; raises low end of prior FY 2014 EPS outlook; gives Q4 2014 outlook in line with analysts' estimates
Wednesday, 22 Oct 2014 07:04am EDT 

Boston Scientific Corp:Expects FY 2014 revenue to be in a range of $7.370 to $7.420 bln (compared to prior guidance of $7.325 to $7.425 bln), which represents growth in a range of 3 to 4 pct on a reported basis and about 5 pct on an operational basis.Expects FY 2014 income on a GAAP basis in a range of $0.22 to $0.24 per share (compared to prior guidance of $0.28 to $0.32).Expects FY 2014 adjusted earnings in a range of $0.81 to $0.83 per share (compared to prior guidance of $0.79 to $0.83).Expects Q4 2014 sales in a range of $1.875 to $1.925 bln.Expects Q4 2014 earnings on a GAAP basis in a range of $0.09 to $0.11 per share.Expects Q4 2014 adjusted earnings, excluding acquisition- and divestiture- and restructuring-related charges and amortization expense, are estimated in a range of $0.20 to $0.22 per share.FY 2014 revenue of $7.385 bln, EPS of $0.82 - Thomson Reuters I/B/E/S.Q4 2014 revenue of $1.918 bln, EPS of $0.21 - Thomson Reuters I/B/E/S.  Full Article

Boston Scientific Corp receives FDA and CE Mark approval for new CoverEdge Surgical Leads For The Precision Spectra Spinal Cord Stimulator (SCS) System
Tuesday, 21 Oct 2014 09:00am EDT 

Boston Scientific Corp:Received U.S. Food and Drug Administration (FDA) and CE Mark approval for CoverEdge 32 and CoverEdge X 32 Surgical Leads, 32-contact surgical leads designed to blanket spinal cord for unprecedented pain coverage.Designed for use with Precision Spectra Spinal Cord Stimulator (SCS) System, CoverEdge Surgical Leads are powered by Illumina 3D Software, anatomy-based computer model for precise pain targeting.Boston Scientific is introducing CoverEdge Surgical Leads at Congress of Neurological Surgeons (CNS) this week in Boston.Previous surgical leads have delivered pain therapy with maximum of 16 independent contacts.  Full Article

Boston Scientific Corp announces that FDA Advisory Committee Panel votes in favor of WATCHMAN Left Atrial Appendage Closure Device
Wednesday, 8 Oct 2014 07:59pm EDT 

Boston Scientific Corp:Says that after reviewing updated data and analysis for Boston Scientific Corp WATCHMAN Left Atrial Appendage Closure (LAAC) Device, U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of Medical Devices Advisory Committee voted in favor of Device.By vote of six to five (with 1 abstention) Panel concluded that benefits of WATCHMAN Device outweigh potential risks.Furthermore, Panel voted that there is reasonable assurance that Device is safe (12 yes to 0 no).On question of reasonable assurance of effectiveness, Panel vote was unfavorable (6 yes to 7 no).Panel provided substantial input and guidance related to proposed Indications for Use and target patient population.There was widespread agreement among Panel members that Device provides much needed alternative to long-term anticoagulation for some patients.While not bound by this vote, FDA takes Advisory Panel comments and recommendations into account when reviewing the WATCHMAN Device application.  Full Article

Boston Scientific Corp receives CE Mark for Vercise Deep Brain Stimulation (DBS) system for treating patients with tremor
Wednesday, 17 Sep 2014 12:00am EDT 

Boston Scientific Corp:Says that it has received CE Mark for Vercise Deep Brain Stimulation (DBS) System for treatment of tremor, including the most common form of this movement disorder known as essential tremor (ET).Tremor is characterized by involuntary and rhythmic shaking, usually associated with difficulty in an activity such as writing or holding and controlling items.  Full Article

Boston Scientific Corp closes acquisition of Interventional Business of Bayer AG
Tuesday, 2 Sep 2014 08:00am EDT 

Boston Scientific Corp:Closes agreement to purchase Interventional business of Bayer AG.Says acquisition enhances tability of Boston Scientific to offer physicians and healthcare systems a more complete portfolio of solutions to treat challenging vascular conditions.  Full Article

Boston Scientific Corporation announces primary endpoint results of NECTAR-HF clinical trial
Saturday, 30 Aug 2014 12:39pm EDT 

Boston Scientific Corporation:Says that it has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial.Says the study evaluated 96 New York Heart Association (NYHA) Class II-III patients with heart failure and an ejection fraction of less than 35 pct.Says all patients continued receiving optimal medical treatment for heart failure, but were randomized 2:1 to treatment or sham (implanted device but not receiving therapy), respectively.The trial did not meet the pre-specified six month primary efficacy endpoint of a reduction in left ventricular end systolic diameter as assessed by a blinded echocardiography core laboratory.Says quality of life metrics demonstrated symptomatic improvement despite the lack of effect on primary and secondary endpoint measures of cardiac remodeling and functional capacity in HF patients.  Full Article

ASAHI INTECC CO LTD forms business alliance with Boston Scientific Corp
Tuesday, 19 Aug 2014 02:30am EDT 

ASAHI INTECC CO LTD:Formalized plans to develop a new differentiated fractional flow reserve (FFR) wire with Boston Scientific Corp.Says joint project focuses on creating a device intended to improve handling compared to existing FFR wires.Agreed to collaborate on key enhancements to the Boston Scientific RotaWire™ Atherectomy Guidewire.  Full Article

Vascular Solutions Inc announces settlement of patent lawsuit with Boston Scientific
Wednesday, 30 Jul 2014 05:29pm EDT 

Vascular Solutions Inc:Reaches settlement of its patent lawsuit with Boston Scientific Corporation relating to patents in area of coronary guide extension catheters.Vascular Solutions filed original lawsuit in U.S. District Court for District of Minnesota in May 2013, alleging that Boston Scientific infringed three patents owned by Vascular Solutions.Patents related to rapid exchange guide extension technology by manufacturing and selling Guidezilla guide extension catheter.Boston Scientific filed counterclaim in July 2013, alleging that Vascular Solutions infringed patent owned by Boston Scientific related to rapid exchange guide extension technology by manufacturing and selling its GuideLiner guide extension catheter.As part of settlement agreement, all litigation between the two parties related to guide extension will be dismissed. The terms of the settlement are confidential.  Full Article

Boston Scientific raises FY 2014 EPS outlook, narrows revenue outlook to a range in line with analysts' estimates; gives Q3 2014 outlook, EPS below analysts' estimates
Thursday, 24 Jul 2014 07:05am EDT 

Boston Scientific Corp:Now expects FY 2014 revenue to be in a range of $7.325 to $7.425 billion (compared to prior guidance of $7.300 to $7.500 billion), which represents growth in a range of 3 to 4 pct on a reported basis and 3 to 5 pct on an operational basis.Now expects income on a GAAP basis in a range of $0.28 to $0.32 per share (compared to prior guidance of $0.36 to $0.41).Adjusted earnings, excluding intangible asset impairment charges, acquisition- and divestiture-, litigation-, and restructuring-related charges and credits, discrete tax items, and amortization expense, in a range of $0.79 to $0.83 per share (compared to prior guidance of $0.77 to $0.82).FY 2014 revenue of $7.393 bln and EPS of $0.80 - Thomson Reuters I/B/E/S.Expects Q3 2014 sales in a range of $1.790 to $1.840 billion.Q3 2014 earnings on a GAAP basis in a range of $0.08 to $0.10 per share.Adjusted earnings, excluding acquisition- and divestiture- and restructuring-related charges and amortization expense, are estimated in a range of $0.18 to $0.20 per share.Q3 2014 revenue of $1.825 bln and EPS of $0.19 - Thomson Reuters I/B/E/S.  Full Article

Boston Scientific Corp receives CE Mark for Agent Drug-Coated Balloon
Wednesday, 23 Jul 2014 05:00pm EDT 

Boston Scientific Corp:Receives CE Mark and begun European market launch of Agent Paclitaxel-Coated PTCA Balloon Catheter.Agent Drug-Coated Balloon (DCB) provides physicians with additional alternative to treat both in-stent restenosis (ISR) and de novo small vessel coronary disease.  Full Article

Transvaginal mesh trial losses put pressure on Boston Scientific

NEW YORK - Boston Scientific Corp’s back-to-back losses in the first two federal trials over its transvaginal mesh devices could drive up the cost of resolving thousands of similar lawsuits, according to legal experts.

Search Stocks